The first successful heart-lung transplantations for cystic fibrosis (CF) were performed in the UK in 1985. Since then our unit has performed 53 such operations. The 2-year survival is 71%'. The majority of patients transplanted are doing well but two of the most serious long-term complications are obliterative bronchiolitis and lymphoproliferative disorders. We are reporting a patient in which both these complications were successfully treated.
Case report
BB a 33-year-old woman with CF had no respiratory symptoms until her late teens when she experienced recurrent pneumothoraces bilaterally which ultimately required tetracycline pleurodesis. Her respiratory function declined steadily and by 1987 she could walk only 10 yards. She underwent a heart-lung transplantation in July 1987. Postoperatively she was immunosuppressed with azathioprine (2 mg/kg/day) and cyclosporin A (to achieve levels of 250-350 ng/ml; whole blood monoclonal antibody assay). Her early postoperative recovery was complicated by an episode of acute pulmonary rejection (which responded to intravenous methylprednisolone 1 g daily for 3 consecutive days) and bone marrow suppression (responding to withdrawal of azathioprine therapy). She remained well with normal lung function until her sixth postoperative month.
Her lung function declined progressively however from the seventh postoperative month. The clinical impression was of chronic lung rejection which failed to respond to high dose steroid therapy, and her respiratory function declined to the extent that artificial ventilation became necessary. In July 1988 she underwent a second heart-lung transplantation. Histological examination of the explanted lungs revealed obliterative bronchiolitis ( Figure 1 ). Postoperatively she required quadruple immunosuppressive therapy (rabbit antithymocyte globulin 100 mg intravenously on alternate days over the first 10 days; methylprednisolone 125 mg intravenously daily for the first 3 postoperative days; cyclosporine A to achieve levels of 500 ng/ml in the first month and thereafter 250-350 ng/ml; azathioprine 2 mg/kg/day). Her initial recovery was complicated by an episode of acute rejection which responded to intravenous methyl prednisolone therapy as before. Two weeks later she Journal of the Royal Society of Medicine Volume 84 September 1991 561 experienced bone marrow suppression once" again which responded to cessation of azathioprine therapy. On the 10th postoperative week, she developed oral ulceration and a widespread maculopapular rash. A skin biopsy was diagnostic of a lymphoproliferative disorder, the histology and T cell markers being consistent with a T cell type ( Figure 2) . The lymphocytes were negative for Epstein-Barr virus nuclear antige~a~d HLTV-l. She was successfully treated by a reduction m her maintenance cyclosporin therapy to whole blood levels of 150 ng/mJ. She remains well 21 months after her second heart-lung transplantation and her respiratory function is normal.
Discussion
Obliterative bronchiolitis is characterized by insidious onset of cough and dyspnoea associated with progressive airflow obs~ruction and loss of lung volume. The chest X-ray is typically clear and often reveals hyperinflated lungs. While Its cause remains unknown, obliterative bronchiolitis is believed to be a type of chronic rejection, although the patient reported here had well-maintained cyclosporin levels.
It has been shown that both pulmonary vascular endothelium and bronchiolar epithelium express Class I and Class II hi.stocompatibility antigens following transplantation'', an~It may be that these antigens provide the target for epithelial injury and ultimately obliterative bronchiolitis. It would also provide an explanation for the histological appearances, for the inflammatory process is not only centred around bronchioles but also involves adjacent lung parenchyma. While this conditions sometimes responds to a prolonged increase in immunosuppression, in many cases steroid therapy is ineffective and the only treatment option remaining is retransplantation. Daily monitoring of the lung function tests may aid the early detection ofthe problem and improve the outcome", Seven of our 53 patients with CF transplanted to date have developed obliterative bronchiolitis; two have died, two await retransplantation and two have stabilized following augmented immunosuppression. The present patient was retransplanted and remains well with no evidence of recurrent lung rejection.
Our patient also developed a T cell cutaneous lymphoproliferative disorder probably related to immunosuppression after her second transplant. This resolved completely following reduction of cyclosporin A dosage. Figure 1. Lung biopsy, haematoxylin and 
